BIO-TECHNE Corp (NASDAQ:TECH) has been assigned a consensus rating of “Buy” from the nine ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $138.00.

Several research firms have commented on TECH. Robert W. Baird reissued a “buy” rating and set a $154.00 target price on shares of BIO-TECHNE in a research report on Thursday. BidaskClub raised BIO-TECHNE from a “hold” rating to a “buy” rating in a research report on Wednesday, January 10th. Zacks Investment Research raised BIO-TECHNE from a “hold” rating to a “buy” rating and set a $143.00 price target on the stock in a research report on Saturday, November 4th. Leerink Swann reaffirmed a “buy” rating on shares of BIO-TECHNE in a research report on Tuesday, December 5th. Finally, Deutsche Bank set a $145.00 price target on BIO-TECHNE and gave the company a “buy” rating in a research report on Tuesday, October 31st.

In other news, Director Robert V. Baumgartner sold 5,000 shares of the firm’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $130.18, for a total value of $650,900.00. Following the sale, the director now directly owns 12,712 shares of the company’s stock, valued at $1,654,848.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.40% of the company’s stock.

Several large investors have recently modified their holdings of TECH. Prudential Financial Inc. grew its position in shares of BIO-TECHNE by 1.4% in the second quarter. Prudential Financial Inc. now owns 23,555 shares of the biotechnology company’s stock valued at $2,768,000 after purchasing an additional 330 shares during the last quarter. JPMorgan Chase & Co. grew its position in BIO-TECHNE by 665.7% during the second quarter. JPMorgan Chase & Co. now owns 6,034 shares of the biotechnology company’s stock worth $709,000 after buying an additional 5,246 shares in the last quarter. Eaton Vance Management grew its position in BIO-TECHNE by 0.4% during the second quarter. Eaton Vance Management now owns 2,566 shares of the biotechnology company’s stock worth $302,000 after buying an additional 9 shares in the last quarter. Wells Fargo & Company MN grew its position in BIO-TECHNE by 7.5% during the second quarter. Wells Fargo & Company MN now owns 49,657 shares of the biotechnology company’s stock worth $5,834,000 after buying an additional 3,475 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in BIO-TECHNE by 1.5% during the second quarter. Alliancebernstein L.P. now owns 25,784 shares of the biotechnology company’s stock worth $3,030,000 after buying an additional 390 shares in the last quarter. 96.96% of the stock is currently owned by institutional investors.

BIO-TECHNE (NASDAQ TECH) opened at $140.02 on Friday. The company has a current ratio of 2.87, a quick ratio of 2.25 and a debt-to-equity ratio of 0.35. The company has a market cap of $5,269.81, a price-to-earnings ratio of 72.55, a price-to-earnings-growth ratio of 3.20 and a beta of 0.75. BIO-TECHNE has a 1 year low of $95.68 and a 1 year high of $141.83.

BIO-TECHNE (NASDAQ:TECH) last posted its earnings results on Tuesday, October 31st. The biotechnology company reported $0.90 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.08. The firm had revenue of $144.61 million for the quarter, compared to the consensus estimate of $142.37 million. BIO-TECHNE had a net margin of 12.54% and a return on equity of 14.11%. The business’s quarterly revenue was up 10.7% on a year-over-year basis. During the same period in the prior year, the business posted $0.84 earnings per share. equities analysts anticipate that BIO-TECHNE will post 3.77 EPS for the current fiscal year.

WARNING: This news story was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2018/01/19/bio-techne-corp-tech-given-consensus-recommendation-of-buy-by-brokerages.html.

BIO-TECHNE Company Profile

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world.

Analyst Recommendations for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.